Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-391-3 | CAS number: 140-01-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Published data, methods and results sufficiently reported to make a judgement.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Removal of zinc from humans by DTPA chelation therapy
- Author:
- Slobodien, M. J.
- Year:
- 1 973
- Bibliographic source:
- 327-30. [Health physics]
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- not applicable
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- no
Test material
- Reference substance name:
- Calcium salt of DTPA
- IUPAC Name:
- Calcium salt of DTPA
- Details on test material:
- - Name of test material (as cited in study report): Na3CaDTPA
Constituent 1
Method
- Type of population:
- other: patient treated by low dose (14 mg/kg/week)-long term DTPA administration
- Subjects:
- - Number of subjects exposed: one
- Sex: Male
- Age: 35
- Race: no data
- Other: height was 5 ft 11 inch. and weight 70 kg, accidental exposure to an 241Am body burden as high as 1.8 µC(14) or 36 times the occupational exposure limit - Ethical approval:
- not specified
- Route of exposure:
- other: no data
- Reason of exposure:
- accidental
- Exposure assessment:
- measured
- Details on exposure:
- The patient accidentally acquired an 241Am body burden as high as 1.8 µC (14) or 36 times the occupational exposure limit
- Examinations:
- - Urine analysis: yes. Daily total urine samples have been collected by the patient in polyethylene containers for subsequent bioassay of 241Am, samples were stored after analyses.
- Haematology: no data
- Lung function parameters: no data
- Other: Fecal samples were collected briefly at the outset of treatment, but was discontinued later - Medical treatment:
- The treatment consists of an I.V. infusion of 1 g Na3CaDTPA in 250 ml saline administered once a week. Daily total urine samples have been collected by the patient in polyethylene containers for subsequent bioassay of 241Am. After 241Am analyses, the remaining samples were stored at -15°C. Fecal samples were collected briefly at the outset of treatment, but this practice had been discontinued. No modification or analyses of the patient’s diet and its zinc content were made.
Zinc analyses were performed on urine samples collected during the last three months
(September-November 1970) of a 5 month rest period, and during a period of treatment with DTPA (December 1970-April 1971). Prior July 1970, the patient had been treated weekly with DTPA for 15 and 19 month periods, separated by a one month rest period.
Results and discussion
- Clinical signs:
- None
- Results of examinations:
- - Urine analysis: The mean daily urine zinc excretion during the baseline period was 0.65 ± 0.13 mg/day (range 0.2-0.9 mg/day) and this was considered normal. The mean daily urinary zinc excretion for the treatment period was 3.15 ± 0.70 mg/day. Zinc excretion levels were highest for the first 24 hours post infusion and then decreased in two stages to a level at or slightly above the baseline value
- Haematology: no data
- Lung function parameters: no data - Effectivity of medical treatment:
- no data
- Outcome of incidence:
- Zinc excretion levels rerurned to a level or slightly above the baseline value
Any other information on results incl. tables
None
Applicant's summary and conclusion
- Conclusions:
- Urinary zinc excretion during 24 hr after i.v. infusion of Na3CaDTPA was 20-30 times greater than the mean daily zinc excretion during a period with no treatment. During the treatment period, the average weekly zinc excretion was increased 5 fold.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.